BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duma C, Kopyov O, Kopyov A, Berman M, Lander E, Elam M, Arata M, Weiland D, Cannell R, Caraway C, Berman S, Scord K, Stemler L, Chung K, Khoudari S, McRory R, Duma C, Farmer S, Bravo A, Yassa C, Sanathara A, Singh E, Rapaport B. Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients. Mol Biol Rep 2019;46:5257-72. [PMID: 31327120 DOI: 10.1007/s11033-019-04983-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Knock E, Julian LM. Building on a Solid Foundation: Adding Relevance and Reproducibility to Neurological Modeling Using Human Pluripotent Stem Cells. Front Cell Neurosci 2021;15:767457. [PMID: 34867204 DOI: 10.3389/fncel.2021.767457] [Reference Citation Analysis]
2 Pemberton HG, Zaki LAM, Goodkin O, Das RK, Steketee RME, Barkhof F, Vernooij MW. Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis-a systematic review. Neuroradiology 2021;63:1773-89. [PMID: 34476511 DOI: 10.1007/s00234-021-02746-3] [Reference Citation Analysis]
3 Li K, Li X, Shi G, Lei X, Huang Y, Bai L, Qin C. Effectiveness and mechanisms of adipose-derived stem cell therapy in animal models of Parkinson's disease: a systematic review and meta-analysis. Transl Neurodegener 2021;10:14. [PMID: 33926570 DOI: 10.1186/s40035-021-00238-1] [Reference Citation Analysis]
4 Taylor ZV, Khand B, Porgador A, Monsonego A, Eremenko E. An optimized intracerebroventricular injection of CD4+ T cells into mice. STAR Protoc 2021;2:100725. [PMID: 34401790 DOI: 10.1016/j.xpro.2021.100725] [Reference Citation Analysis]
5 Sekiya T, Holley MC. Cell Transplantation to Restore Lost Auditory Nerve Function is a Realistic Clinical Opportunity. Cell Transplant 2021;30:9636897211035076. [PMID: 34498511 DOI: 10.1177/09636897211035076] [Reference Citation Analysis]
6 Caballero-Villarraso J, Sawas J, Escribano BM, Martín-Hersog FA, Valverde-Martínez A, Túnez I. Gene and cell therapy and nanomedicine for the treatment of multiple sclerosis: bibliometric analysis and systematic review of clinical outcomes. Expert Rev Neurother 2021;21:431-41. [PMID: 33554666 DOI: 10.1080/14737175.2021.1886926] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bunnell BA. Adipose Tissue-Derived Mesenchymal Stem Cells. Cells 2021;10:3433. [PMID: 34943941 DOI: 10.3390/cells10123433] [Reference Citation Analysis]
8 Prpar Mihevc S, Kokondoska Grgich V, Kopitar AN, Mohorič L, Majdič G. Neural differentiation of canine mesenchymal stem cells/multipotent mesenchymal stromal cells. BMC Vet Res 2020;16:282. [PMID: 32778115 DOI: 10.1186/s12917-020-02493-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Pan H, Qiu H, Zhang K, Zhang P, Liang W, Yang M, Mou C, Lin M, He M, Xiao X, Zhang D, Wang H, Liu F, Li Y, Jin H, Yan X, Liang H, Cui W. Fascaplysin Derivatives Are Potent Multitarget Agents against Alzheimer’s Disease: in Vitro and in Vivo Evidence. ACS Chem Neurosci 2019;10:4741-56. [DOI: 10.1021/acschemneuro.9b00503] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
10 de Melo GD, Sonthonnax F, Lepousez G, Jouvion G, Minola A, Zatta F, Larrous F, Kergoat L, Mazo C, Moigneu C, Aiello R, Salomoni A, Brisebard E, De Benedictis P, Corti D, Bourhy H. A combination of two human monoclonal antibodies cures symptomatic rabies. EMBO Mol Med 2020;12:e12628. [PMID: 32945125 DOI: 10.15252/emmm.202012628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Gugliandolo A, Bramanti P, Mazzon E. Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies. Int J Mol Sci 2020;21:E8662. [PMID: 33212873 DOI: 10.3390/ijms21228662] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
12 Hanes J, Dobakova E, Majerova P. Brain Drug Delivery: Overcoming the Blood-brain Barrier to Treat Tauopathies. Curr Pharm Des 2020;26:1448-65. [PMID: 32178609 DOI: 10.2174/1381612826666200316130128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kawabori M, Shichinohe H, Kuroda S, Houkin K. Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke. Int J Mol Sci 2020;21:E7380. [PMID: 33036265 DOI: 10.3390/ijms21197380] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Vissers MFJM, Heuberger JAAC, Groeneveld GJ. Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders. Int J Mol Sci 2021;22:1615. [PMID: 33562713 DOI: 10.3390/ijms22041615] [Reference Citation Analysis]
15 Smith JA, Nicaise AM, Ionescu RB, Hamel R, Peruzzotti-Jametti L, Pluchino S. Stem Cell Therapies for Progressive Multiple Sclerosis. Front Cell Dev Biol 2021;9:696434. [PMID: 34307372 DOI: 10.3389/fcell.2021.696434] [Reference Citation Analysis]
16 Naseri Kouzehgarani G, Feldsien T, Engelhard HH, Mirakhur KK, Phipps C, Nimmrich V, Clausznitzer D, Lefebvre DR. Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues. Adv Drug Deliv Rev 2021;173:20-59. [PMID: 33705875 DOI: 10.1016/j.addr.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Tsui YP, Lam G, Wu KL, Li MT, Tam KW, Shum DK, Chan YS. Derivation of Oligodendrocyte Precursors from Adult Bone Marrow Stromal Cells for Remyelination Therapy. Cells 2021;10:2166. [PMID: 34440935 DOI: 10.3390/cells10082166] [Reference Citation Analysis]